Safety Evaluation Study for Patients With Polycythemia Vera
This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera
Polycythemia Vera
DRUG: PPMX-T003
Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in the Study, 45 weeks
Evaluation of pharmacokinetics of PPMX-T003 after single dose, Observed maximum plasma concentration \[Cmax\], Day1,Day2,Day7|Evaluation of pharmacokinetics of PPMX-T003 after single dose, Terminal elimination rate constant \[λz\], Day1,Day2,Day7|Evaluation of pharmacokinetics of PPMX-T003 after single dose, Area under the concentration-time curve from pre-dose \[time 0\] to the time of the last quantifiable concentration \[AUC0-t\], Day1,Day2,Day7|Evaluation of pharmacokinetics of PPMX-T003 after single dose, Area under the concentration-time curve from pre-dose \[time 0\] extrapolated to infinite time \[AUC0-inf\], Day1,Day2,Day7|Evaluation of pharmacokinetics of PPMX-T003 after single dose, Apparent terminal half-life \[t½\], Day1,Day2,Day7|Evaluation of pharmacokinetics of PPMX-T003 after single dose, Apparent systemic clearance \[CL\], Day1,Day2,Day7|Evaluation of pharmacokinetics of PPMX-T003 after single dose, Volume of distribution \[Vd\], Day1,Day2,Day7|Examining the expression rate of anti-drug antibodies (ADA), Day1,Day21,up to 45weeks
This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera